3 September 2020

Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indication.

Santhera has exercised its’ option to obtain worldwide rights to vamorolone in DMD and all other indications. The license gives Santhera worldwide rights to vamorolone and gives the company immediate control over the vamorolone development program.

This provides Santhera with the advantage of full control of vamorolone and allows them to pursue development, registration, and commercialisation more effectively and efficiently – which the company consider to be a very good thing for patients and their families.

This news establishes Santhera as a leading company in the quest to achieving more effective treatments and ultimately a cure for Duchenne, with two late-stage therapies that address the medical needs of boys and men with Duchenne through all stages of their disease.

To read the full press release, please click the link below:

2020-06-02_Vamorolone_LTE_e_final